Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
10 Nov 2020
Historique:
entrez: 10 11 2020
pubmed: 11 11 2020
medline: 20 11 2020
Statut: ppublish

Résumé

Prevalence of hypertension (both primary and secondary) in children and adolescents in the US ranges from 3% to 4%. Primary hypertension in children and adolescents occurs primarily in children older than 13 years and has no known cause but is associated with several risk factors, including family history and higher body mass index. Secondary hypertension occurs primarily in younger children and is most commonly caused by genetic disorders, renal disease, endocrine disorders, or cardiovascular abnormalities. To update its 2013 recommendation, the USPSTF commissioned a review of the evidence on the benefits and harms of screening, test accuracy, the effectiveness and harms of treatment, and the association between hypertension and markers of cardiovascular disease in childhood and adulthood. This recommendation statement applies to children and adolescents aged 3 to 18 years not known to have hypertension or who are asymptomatic. The USPSTF concludes that the evidence to support screening for high blood pressure in children and adolescents is insufficient and that the balance of benefits and harms cannot be determined. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for high blood pressure in children and adolescents. (I statement).

Identifiants

pubmed: 33170248
pii: 2772767
doi: 10.1001/jama.2020.20122
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1878-1883

Commentaires et corrections

Type : CommentIn
Type : SummaryForPatientsIn

Auteurs

Alex H Krist (AH)

Fairfax Family Practice Residency, Fairfax, Virginia.
Virginia Commonwealth University, Richmond.

Karina W Davidson (KW)

Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York.

Carol M Mangione (CM)

University of California, Los Angeles.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Michael Cabana (M)

University of California, San Francisco.

Aaron B Caughey (AB)

Oregon Health & Science University, Portland.

Katrina Donahue (K)

University of North Carolina at Chapel Hill.

Chyke A Doubeni (CA)

Mayo Clinic, Rochester, Minnesota.

John W Epling (JW)

Virginia Tech Carilion School of Medicine, Roanoke.

Martha Kubik (M)

George Mason University, Fairfax, Virginia.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

Michael Silverstein (M)

Boston University, Boston, Massachusetts.

Melissa A Simon (MA)

Northwestern University, Evanston, Illinois.

Chien-Wen Tseng (CW)

University of Hawaii, Honolulu.
Pacific Health Research and Education Institute, Honolulu, Hawaii.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH